A Phase 2 interventional study of MVA-NP+M1 and Saline in Influenza, sponsored by Barinthus Biotherapeutics. Terminated at 9 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-26.
Sponsored by Barinthus Biotherapeutics · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Influenza, Human with a site in Australia — 8 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · Australia.
Among the 99 studies in Influenza, Human with a site in Australia, this one is the 13th largest by enrollment of the 87 interventional ones that give a count, is one of 4 that started in 2019, is one of 27 in phase 2, and was the 65th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →8 of the 99 studies in Influenza, Human with a site in Australia are open now. Recruiting first, the newest first:
Traws Pharma, Inc. · Sites in Australia
Ages 18–65 · Healthy volunteers
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Sites in Australia, United States, Argentina and 3 more countries
Ages 12+
Vaxine Pty Ltd · Sites in Australia
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in Australia, United States, Argentina and 36 more countries
Ages 18+
University of Adelaide · Sites in Australia
Ages 6 mo+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 31 · Phase 3 26 · Phase 4 3
First in 2001; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,364 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 360 across the 87 interventional studies, 1,000 across the 11 observational. Of the 81 that completed or were terminated, 31 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
85 of 99 have an industry lead sponsor. The 10 most frequent:
Barinthus Biotherapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Barinthus Biotherapeutics has 3 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
4 of the studies in Influenza, Human with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07371650Traws Pharma, Inc.This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza | 2026-12 |
| NCT07516418SanofiStudy of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | 2027-04-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 99 studies in Influenza, Human with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct to licensed quadrivalent influenza vaccine (QIV) in adults
This is a Phase 2b, multicentre, randomised, single-blind study in up to 6000 adults to compare the efficacy, safety and immunogenicity of MVA-NP+M1 when given as an adjunct to a standard, licensed adult dose of QIV. The study will be conducted on an outpatient basis and will run over two consecutive influenza seasons. It is aimed to recruit 2200 participants in Season 1 and 2800-3800 participants in Season 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible for this study if she is not pregnant or breast feeding and one of the following:
i. Male partner who is sterile prior to the female participant's entry into the study and is the sole sexual partner for the female participant ii. Implants of levonorgestrel iii. Injectable progestogen iv. An intrauterine device with a documented failure rate of \<1% v. Oral contraceptives vi. Double barrier methods including diaphragm or condom vii. Abstinence as long as it is line with the usual and preferred lifestyle of the participant
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\^8 pfu.)
Biological: MVA-NP+M1
Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)
Drug: Saline
Drug page: MVA-NP+M1Studies of MVA-NP+M1MVA-NP+M1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Trial Vaccine
Sodium Chloride Placebo
Also known as: Placebo
Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR).
The measure used reverse transcription polymerase chain reaction (RT-PCR) on deep nasal/mid-turbinate swab samples to record confirmed cases of influenza. If influenza symptoms are experienced at any time during the Follow Up period, after the vaccination, participants will attend the clinic on two occasions, the first as soon as possible and at least within 72 hours of the onset of symptoms for deep nasal swabs to be taken. Both swabs must be taken within 96 hours of symptom onset. The incidence rate of laboratory confirmed influenza using RT-PCR will be estimated for each vaccine group. The 95% CI for the incidence rate will be estimated by mid-p exact method. The difference in incidence rate between vaccine groups will be compared by Fisher's exact method.
Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019) in line with official Australian influenza season.
Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary
ILI is defined as feeling feverish or having a fever (feeling feverish or having a fever (≥37.8Celsius)) and at least one of the following symptoms: cough, sore throat. The incidence rate of ILI by the participant completing of eDiaries will be estimated for each vaccine group. The 95% CI for the incidence will be estimated by mid-p exact method. The difference in incidence between groups will be compared by Fisher's exact method.
Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)
Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs)
The solicited adverse events are commonly observed soon after receipt of vaccines and relate to local and systemic signs and symptoms. The solicited local injection site reactions (ISR) include pain, induration, warmth, and erythema (redness). The solicited systemic reactions include feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, and malaise. Participants completed eDiaries post vaccination to record ISR and systemic reactogenicity over the first 7 days post-vaccination (and the ongoing (S)AEs throughout the study). The participant reporting of all ISR categories and solicited systemic reactions was compared between the MVA-NP+M1 treated group and the Placebo treated group. Diary reported ISRs and solicited systemic reactions were summarized, by vaccination group, using descriptive statistics.
Time frame: 7 days to a total of 210 days for SAEs (over the duration of the influenza season, between 01 May and 15 October)
Number of Participants With Immunogenic Response (Immunogenicity of MVA-NP+M1 in Adjunction With Licensed QIV as Assessed Via Titres of Influenza-specific Neutralizing Antibodies)
The numbers of Immunogenic Participants (participants with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were summarized and listed. The immunogenicity here was assessed as the geometric mean titers of influenza-specific neutralizing antibodies at different timepoints in relation to the baseline, against the antigens included in the licensed QIV(Influenza A/H3N2 (HI), Influenza A/H3N2 (MN), Influenza A/H3N2 (H1N1pdm), Influenza B/Victoria, and Influenza B/Yamagata). The neutralizing antibody assays included microneutralisation and hemagglutination inhibition titers using standard methodologies for the four strains that were in the licensed vaccine. The immunogenicity analyses were conducted only on the Immunology Analysis Set of Participants.
Time frame: Day 28 and Week 26
Duration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary
The duration of ILI is defined as the duration (days) from the first day ILI criteria met (as defined at the Secondary Outcome Measure 2) until the first day afterwards ILI criteria not met (event, ILI recovery). ILI positive participants with ILI criteria met throughout the entire influenza season were censored at the last day recorded with the ILI dairy. Survival analysis was used for the analysis of duration of ILI. The survival function for the duration of ILI was estimated by the Kaplan-Meier method.
Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)
Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC
The severity of ILI was assessed by each participant completing of electronic Diaries for symptom severity daily for the following symptoms: Feeling hot, Temperature, Cough, Sore throat, Blocked nose, Chest pain, Muscle aches, Shortness of breath with their severities (scores) recorded as: Not Present (0), Mild (1), Moderate (2), Severe (3). For each symptom, the severity score was used to calculate the area under the curve (AUC), along with the calendar day, for the entire influenza season using trapezoidal rule. Participants could be followed for varying days in the influenza season, therefore the AUC will be time weighted to 168 days: Time weighted AUC=((raw AUC \[time in days\])/(number of days used for analysis)) \* 168
Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)
Number of Participants With Immunogenic Response to MVA-NP+M1 (as Assessed Via the Frequency of Influenza-specific T-cells)
The numbers of immunogenic Participants (with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were listed. The immunogenicity here was determined via the frequency of influenza-specific T-cells measured by IFN-γ/granzyme B ELISpot assay (enzyme linked immunospot) where the adjusted Spot Forming Units (SFU) per million PBMCs (peripheral blood mononuclear cells) after background subtraction (dimethyl sulfoxide, DMSO) were counted. The immunogenicity analyses were conducted only in the Immunology Analysis Set of Participants.
Time frame: Day 28 and Week 26
The single-blind study was conducted at 9 sites across Australia, over one Influenza season.
| Milestone | MVA-NP+M1 Group (Main Cohort + Immunogenicity Cohort) | Saline Placebo Group (Main Cohort+ Immunogenicity Cohort) |
|---|---|---|
| Started | 1077 | 1075 |
| Completed | 1054 | 1055 |
| Not completed | 23 | 20 |
The measure used reverse transcription polymerase chain reaction (RT-PCR) on deep nasal/mid-turbinate swab samples to record confirmed cases of influenza. If influenza symptoms are experienced at any time during the Follow Up period, after the vaccination, participants will attend the clinic on two occasions, the first as soon as possible and at least within 72 hours of the onset of symptoms for deep nasal swabs to be taken. Both swabs must be taken within 96 hours of symptom onset. The incidence rate of laboratory confirmed influenza using RT-PCR will be estimated for each vaccine group. The 95% CI for the incidence rate will be estimated by mid-p exact method. The difference in incidence rate between vaccine groups will be compared by Fisher's exact method.
| Participants | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| Participants with laboratory confirmed influenza using RT-PCR | 35 | 23 |
| Participants without laboratory confirmed influenza using RT-PCR | 1042 | 1052 |
ILI is defined as feeling feverish or having a fever (feeling feverish or having a fever (≥37.8Celsius)) and at least one of the following symptoms: cough, sore throat. The incidence rate of ILI by the participant completing of eDiaries will be estimated for each vaccine group. The 95% CI for the incidence will be estimated by mid-p exact method. The difference in incidence between groups will be compared by Fisher's exact method.
| Participants | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| Positive ILI Cases | 273 | 273 |
| Negative ILI Cases | 804 | 802 |
The solicited adverse events are commonly observed soon after receipt of vaccines and relate to local and systemic signs and symptoms. The solicited local injection site reactions (ISR) include pain, induration, warmth, and erythema (redness). The solicited systemic reactions include feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, and malaise. Participants completed eDiaries post vaccination to record ISR and systemic reactogenicity over the first 7 days post-vaccination (and the ongoing (S)AEs throughout the study). The participant reporting of all ISR categories and solicited systemic reactions was compared between the MVA-NP+M1 treated group and the Placebo treated group. Diary reported ISRs and solicited systemic reactions were summarized, by vaccination group, using descriptive statistics.
| Participants | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| Participants with Solicited Local Injection Site Reaction (IRS) - Pain | 292 | 19 |
| Participants with Solicited Local Injection Site Reaction (IRS) - Induration | 113 | 4 |
| Participants with Solicited Local Injection Site Reaction (IRS) - Warmth | 205 | 18 |
| Participants with Solicited Local Injection Site Reaction (IRS) - Erythema | 198 | 15 |
| Participants with Severe, Solicited Local Injection Site Reaction | 12 | 1 |
| Participants with Solicited Systemic Reactions - Chills | 61 | 18 |
| Participants with Solicited Systemic Reactions - Myalgia | 256 | 85 |
| Participants with Solicited Systemic Reactions - Fatigue | 248 | 117 |
| Participants with Solicited Systemic Reactions - Headache | 238 | 106 |
| Participants with Solicited Systemic Reactions - Nausea | 88 | 31 |
| Participants with Solicited Systemic Reactions - Arthralgia | 156 | 57 |
| Participants with Solicited Systemic Reactions - Malaise | 273 | 139 |
| Participants with Solicited Systemic Reactions - Feverishness | 214 | 93 |
| Participants with Severe, Solicited Systemic Reaction | 45 | 14 |
The numbers of Immunogenic Participants (participants with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were summarized and listed. The immunogenicity here was assessed as the geometric mean titers of influenza-specific neutralizing antibodies at different timepoints in relation to the baseline, against the antigens included in the licensed QIV(Influenza A/H3N2 (HI), Influenza A/H3N2 (MN), Influenza A/H3N2 (H1N1pdm), Influenza B/Victoria, and Influenza B/Yamagata). The neutralizing antibody assays included microneutralisation and hemagglutination inhibition titers using standard methodologies for the four strains that were in the licensed vaccine. The immunogenicity analyses were conducted only on the Immunology Analysis Set of Participants.
| Participants | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| Participants with Influenza Antibody Titer: ANCOVA Analysis Immunology, at Day 28 | 23 | 24 |
| Participants with Influenza Antibody Titer: ANCOVA Analysis Immunology, at Week 26 | 23 | 25 |
The duration of ILI is defined as the duration (days) from the first day ILI criteria met (as defined at the Secondary Outcome Measure 2) until the first day afterwards ILI criteria not met (event, ILI recovery). ILI positive participants with ILI criteria met throughout the entire influenza season were censored at the last day recorded with the ILI dairy. Survival analysis was used for the analysis of duration of ILI. The survival function for the duration of ILI was estimated by the Kaplan-Meier method.
| days | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| Duration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary | 3 (3 to 4) | 3 (3 to 4) |
The severity of ILI was assessed by each participant completing of electronic Diaries for symptom severity daily for the following symptoms: Feeling hot, Temperature, Cough, Sore throat, Blocked nose, Chest pain, Muscle aches, Shortness of breath with their severities (scores) recorded as: Not Present (0), Mild (1), Moderate (2), Severe (3). For each symptom, the severity score was used to calculate the area under the curve (AUC), along with the calendar day, for the entire influenza season using trapezoidal rule. Participants could be followed for varying days in the influenza season, therefore the AUC will be time weighted to 168 days: Time weighted AUC=((raw AUC \[time in days\])/(number of days used for analysis)) \* 168
| weighted days | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC | 5490 ± 23.4944 | 5297 ± 21.3996 |
The numbers of immunogenic Participants (with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were listed. The immunogenicity here was determined via the frequency of influenza-specific T-cells measured by IFN-γ/granzyme B ELISpot assay (enzyme linked immunospot) where the adjusted Spot Forming Units (SFU) per million PBMCs (peripheral blood mononuclear cells) after background subtraction (dimethyl sulfoxide, DMSO) were counted. The immunogenicity analyses were conducted only in the Immunology Analysis Set of Participants.
| Participants | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| Participants with immunogenic response (as the frequency of influenza-specific T-cells) at Day 28 | 20 | 21 |
| Participants with Immunogenic response (via the frequency of influenza-specific T-cells) at Week 26 | 16 | 13 |
Collected over Unsolicited non-serious adverse events will be collected for 28 days post-vaccination. Hospitalisations, other serious adverse events and or adverse events of special interest will be collected for the duration of the influenza season. Solicited adverse events, including solicited local injection site reactions (ISR) and solicited systemic reactions, will be collected for 7 days post-vaccination. These will be recorded daily in the eDiary for all participants.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MVA-NP+M1 Group | 0/1,077 (0%) | 18/1,077 (1.7%) | 524/1,077 (48.7%) |
| Saline Placebo Group | 1/1,075 (0.1%) | 22/1,075 (2%) | 435/1,075 (40.5%) |
| Event | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| PneumoniaInfections and infestations | 2/1077 | 3/1075 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/1077 | 2/1075 |
| DiverticulitisInfections and infestations | 1/1077 | 1/1075 |
| AppendicitisInfections and infestations | 0/1077 | 1/1075 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 0/1077 | 1/1075 |
| Pneumonia mycoplasmalInfections and infestations | 0/1077 | 1/1075 |
| Pyelonephritis acuteInfections and infestations | 0/1077 | 1/1075 |
| TonsillitisInfections and infestations | 0/1077 | 1/1075 |
| COPDRespiratory, thoracic and mediastinal disorders | 1/1077 | 1/1075 |
| Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders | 0/1077 | 1/1075 |
| Event | MVA-NP+M1 Group | Saline Placebo Group |
|---|---|---|
| HeadacheNervous system disorders | 145/1077 | 122/1075 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 115/1077 | 119/1075 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 89/1077 | 93/1075 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 90/1077 | 84/1075 |
| CoughRespiratory, thoracic and mediastinal disorders | 73/1077 | 86/1075 |
| Injection site painGeneral disorders | 73/1077 | 0/1075 |
| MyalgiaMusculoskeletal and connective tissue disorders | 59/1077 | 36/1075 |
| FatigueGeneral disorders | 43/1077 | 24/1075 |
| Upper respiratory tract infectionInfections and infestations | 20/1077 | 31/1075 |
| PyrexiaGeneral disorders | 30/1077 | 0/1075 |
| Age, Continuous(years) | MVA-NP+M1 Group | Saline Placebo Group | Total |
|---|---|---|---|
| Mean | 43.6 ± 18.93 | 43.8 ± 18.40 | 43.7 ± 18.66 |
| Sex/Gender, Customized(Participants) | MVA-NP+M1 Group | Saline Placebo Group | Total |
|---|---|---|---|
| Female | 631 | 631 | 1262 |
| Male | 445 | 443 | 888 |
| Unknown | 1 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | MVA-NP+M1 Group | Saline Placebo Group | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 11 | 21 |
| Not Hispanic or Latino | 1061 | 1052 | 2113 |
| Unknown or Not Reported | 6 | 12 | 18 |
| Race (NIH/OMB)(Participants) | MVA-NP+M1 Group | Saline Placebo Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 143 | 118 | 261 |
| Native Hawaiian or Other Pacific Islander | 8 | 13 | 21 |
| Black or African American | 9 | 7 | 16 |
| White | 882 | 892 | 1774 |
| More than one race | 5 | 3 | 8 |
| Unknown or Not Reported | 29 | 42 | 71 |
| Body Mass Index (BMI)(kg/m^2) | MVA-NP+M1 Group | Saline Placebo Group | Total |
|---|---|---|---|
| Mean | 28.36 ± 6.727 | 28.26 ± 6.143 | 28.31 ± 6.435 |
| Body Temperature(degree Celsius) | MVA-NP+M1 Group | Saline Placebo Group | Total |
|---|---|---|---|
| Mean | 36.44 ± 0.420 | 36.44 ± 0.401 | 36.44 ± 0.410 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Oct 2019, 6 months.
Results were first posted in Apr 2021, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MVA-NP+M1
Barinthus Biotherapeutics